Approval · Notice of Compliance 38441 · 2026
RIVA SITAGLIPTIN: Notice of Compliance 38441
Issued October 9, 2026
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 38441
- Date
- October 9, 2026
- Company
- Laboratoire Riva Inc.Blainville, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Admin
- Reason
- Administrative: Licensing Agreement between two manufacturers
- Canadian reference product
- JANUVIA (Merck Canada Inc)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| RIVA SITAGLIPTIN | 02572419 | — |
| RIVA SITAGLIPTIN | 02572427 | — |
| RIVA SITAGLIPTIN | 02572435 | — |
Medicinal ingredients
- SITAGLIPTIN PHOSPHATE MONOHYDRATE 25 MG per TAB
- SITAGLIPTIN PHOSPHATE MONOHYDRATE 50 MG per TAB
- SITAGLIPTIN PHOSPHATE MONOHYDRATE 100 MG per TAB